Clinical and experimental obstetrics & gynecology · 2011
Distribution of etiological factors of hypergonadotropic amenorrhea.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Meden-Vrtovec H, Gersak K, Franić D
Аннотация
OBJECTIVE: To describe the etiology of hypergonadotropic amenorrhea (HA) and outline the subgroup of infertile women that might achieve pregnancy with their own eggs despite premature ovarian failure.
METHODS: In this retrospective study we enrolled 70 women aged 32.5 +/- 5.71 years. After a detailed history of the disease, measurements of follicle-stimulating hormone, estradiol, prolactin and thyroid-stimulating hormone levels, determination of the karyotype and fragile X premutation syndrome, and a quick ACTH test, estrogen-progestin replacement therapy was introduced.
RESULTS: In 17 of the 70 women, HA was due to chromosomal abnormalities, in 16 to extensive gynecologic surgery, in ten to oral contraceptive use, in four to chemo- and radiotherapy; in 23 HA was idiopathic. After estrogen-progestin replacement therapy, three women with idiopathic HA conceived and delivered healthy babies.
CONCLUSION: Estrogen-progestin replacement therapy in pharmacological doses might be beneficial to women with idiopathic HA, having normal prolactin levels, adrenal and thyroid function, and a normal karyotype.
METHODS: In this retrospective study we enrolled 70 women aged 32.5 +/- 5.71 years. After a detailed history of the disease, measurements of follicle-stimulating hormone, estradiol, prolactin and thyroid-stimulating hormone levels, determination of the karyotype and fragile X premutation syndrome, and a quick ACTH test, estrogen-progestin replacement therapy was introduced.
RESULTS: In 17 of the 70 women, HA was due to chromosomal abnormalities, in 16 to extensive gynecologic surgery, in ten to oral contraceptive use, in four to chemo- and radiotherapy; in 23 HA was idiopathic. After estrogen-progestin replacement therapy, three women with idiopathic HA conceived and delivered healthy babies.
CONCLUSION: Estrogen-progestin replacement therapy in pharmacological doses might be beneficial to women with idiopathic HA, having normal prolactin levels, adrenal and thyroid function, and a normal karyotype.